- My former FTC colleague David Wales joins Jones Day
- The CATO “New Course for Antitrust” video is now available for your viewing pleasure
- Microsoft on the release of Windows 7 in Europe without IE
- The FTC issues its interim report on authorized generics and Chairman Leibowitz claims that reverse payment settlements (based on a Bureau of Economics analysis) cost consumers at least $35 billion over 10 years
testing
I thought Rosch’s critique was very good. Narrowly and appropriately focused on methodological and interpretive problems, I think he did a good job indicating some important limits of the study. No doubt the dynamic effects are completely absent from the report and its assessment by Leibowitz.
What — no mention of Rosch’s critique of the AG report?
BTW, so far as I can tell Liebowitz’s figures do not take into account the dynamic costs to innovation (and other incentives) that a change in the rules could have. Obviously those are tougher to measure, but if you’re talking 10 years they ought to be accounted for.